Asthma Respiratory Asthma
Conditions
Interventions
Oral montelukast 10 mg once daily for 8 weeks is given to all patients. Follow-up at 8 weeks.
Sponsors
University of East Anglia (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female, aged 18 to 60 years 2. Diagnosed with asthma, defined as episodic chest tightness, wheezing and dyspnoea, cough 3. Non-smoker or ex-smoker for at least 10 years and a smoking history of less than 5 pack years 4. History of asthma symptoms for more than 10 years 5. Receiving as required short acting bronchodilators 6. Post-bronchodilator forced expiratory volume in one second (FEV1) 50 - 100% predicted 7. Evidence of airway calibre reversibility within the previous 12 months: reversibility to salbutamol of 12% following 400 µg inhaled salbutamol, histamine PC20 less than 8 mg/ml, diurnal variation in peak expiratory flow of 20% 8. Able to produce sputum after induction with saline
Exclusion criteria
Exclusion criteria: 1. Cardiac or pulmonary disease other than asthma 2. Respiratory infection defined as fever, nasal/sinus congestion, fatigue, cough, antibiotic use or yellow/green sputum within 4 weeks prior to study 3. Receiving inhaled or oral corticosteroid therapy, long acting ?Ò2 agonist therapy or leukotriene modifying therapy for the previous 1 month 4. Severe or uncontrolled co-morbid disease 5. Pregnancy or breastfeeding 6. Unable to give written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Induced sputum mRNA of matrix metalloproteinase (MMP) and tissue inhibitors of MMPs (TIMPs), measured before and after 8 weeks of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
United Kingdom
Outcome results
None listed